Watchlist Price Alert

Agios Pharmaceuticals Inc... (AGIO)

NASDAQ: AGIO · Real-Time Price · USD

30.07

-0.03 (-0.10%)

At close: May 05, 2025, 3:59 PM

29.97

-0.33%

After-hours: May 05, 2025, 04:20 PM EDT

-0.10% (1D)

Bid	26.78
Market Cap	1.74B
Revenue (ttm)	37.03M
Net Income (ttm)	665.99M
EPS (ttm)	11.64
PE Ratio (ttm)	2.58
Forward PE	-4.95
Analyst	Buy

Ask	31.99
Volume	262,151
Avg. Volume (20D)	684,240
Open	29.89
Previous Close	30.10
Day's Range	29.89 - 31.47
52-Week Range	23.42 - 62.58
Beta	0.83

About AGIO

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Ph...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 24, 2013

Employees 486

Stock Exchange NASDAQ

Ticker Symbol AGIO

Website https://www.agios.com

Full Company Profile

Analyst Forecast

According to 9 analyst ratings, the average rating for AGIO stock is "Buy." The 12-month stock price forecast is $55, which is an increase of 82.91% from the latest price.

Stock Forecasts

Earnings Surprise

Agios Pharmaceuticals has released their quartely earnings on May 1, 2025:

Revenue of $8.73M misses estimates by $954K, with 6.56% YoY growth.

EPS of -1.55 exceeds estimates by 0.21, with -6.90% YoY decline.

Why Price Moved

6 months ago

-4.04%

Agios Pharmaceuticals shares are trading lower aft... Unlock content with Pro Subscription

7 months ago

-5.08%

Agios Pharmaceuticals shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and cut its price target on the stock from $60 to $56.

News

3 days ago · zacks.com

Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates

AGIO's earnings beat estimates in the first quarter of 2025, while revenues miss the same.

5 days ago · seekingalpha.com

Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Chris Taylor – Vice President-Investor Relations and Corporate Communications Br...

4 days ago · zacks.com

Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates

Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.55 per share versus the Zacks Consensus Estimate of a loss of $1.80. This compares to loss of $1.45 per share a year ago.

1 week ago · zacks.com

Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago · zacks.com

New Strong Sell Stocks for April 8th

AFLYY, AGIO and ARLP have been added to the Zacks Rank #5 (Strong Sell) List on April 8, 2025.

1 month ago · zacks.com

New Strong Sell Stocks for April 3rd

AGIO, CHGG and EFX have been added to the Zacks Rank #5 (Strong Sell) List on April 3, 2025.

2 months ago · zacks.com

Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues

AGIO reports mixed fourth-quarter 2024 results. Its sole marketed drug, Pyrukynd, drives revenues year over year.

2 months ago · seekingalpha.com

Agios Pharmaceuticals, Inc. (AGIO) Q4 2024 Earnings Call Transcript

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Brian Goff - CEO Sarah Gheuens - CMO & Head OF R&D Tsveta Milanova - CCO C...

2 months ago · zacks.com

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates

Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.74 per share versus the Zacks Consensus Estimate of a loss of $1.73. This compares to loss of $1.72 per share a year ago.